You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 5, 2024

Details for Patent: 10,251,896


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,251,896 protect, and when does it expire?

Patent 10,251,896 protects RELYVRIO and is included in one NDA.

This patent has forty-two patent family members in nineteen countries.

Summary for Patent: 10,251,896
Title:Compositions for improving cell viability and methods of use thereof
Abstract:This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
Inventor(s):Cohen Joshua, Klee Justin
Assignee:Amylyx Pharmaceuticals Inc.
Application Number:US15837866
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 10,251,896

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,251,896

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014242123 ⤷  Sign Up
Australia 2019200658 ⤷  Sign Up
Australia 2021201770 ⤷  Sign Up
Australia 2022221410 ⤷  Sign Up
Canada 2908683 ⤷  Sign Up
China 105050593 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.